AtaiBeckley Inc.

AtaiBeckley is a clinical-stage biotechnology company founded in 2025 through the combination of atai Life Sciences N.V. and Beckley Psytech Limited. The company focuses on developing treatments for difficult-to-treat mental health conditions, addressing a global prevalence of over one billion people and a substantial economic burden, estimated to reach $16.0 trillion by 2030. Despite existing treatments like SSRIs and SNRIs, approximately 65% of patients do not achieve symptom remission after up to four antidepressant trials, indicating a significant unmet medical need. AtaiBeckley aims to develop effective, rapid-acting, and convenient treatments. Its diversified pipeline includes investigational psychedelic-based neuroplastogens. Key programs are: BPL-003, a nasal spray mebufotenin (5-MeO-DMT) benzoate for treatment-resistant depression (TRD); VLS-01, a buccal film dimethyltryptamine (DMT) for TRD; EMP-01, an oral formulation of R-MDMA for social anxiety disorder (SAD); and a drug discovery program for novel, non-hallucinogenic 5-HT2AR agonists for TRD and Opioid Use Disorder (OUD). The company believes psychedelics are emerging as breakthrough therapies for mental health disorders.